These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 12435172

  • 61. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S, Spirko R, Law A, Dennis VW.
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [Abstract] [Full Text] [Related]

  • 62. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C.
    J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
    [Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64. Every-three-week administration of darbepoetin alfa in women with chemotherapy-associated anemia.
    Goram AL.
    Am J Health Syst Pharm; 2006 Aug 15; 63(16):1522-7. PubMed ID: 16896080
    [Abstract] [Full Text] [Related]

  • 65. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy.
    Agoram B, Heatherington AC, Gastonguay MR.
    AAPS J; 2006 Sep 01; 8(3):E552-63. PubMed ID: 17025273
    [Abstract] [Full Text] [Related]

  • 66. Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency.
    Glaspy JA.
    Oncology (Williston Park); 2002 Sep 01; 16(9 Suppl 10):71-7. PubMed ID: 12380957
    [Abstract] [Full Text] [Related]

  • 67. Darbepoetin alfa is improved therapy for chemotherapy-induced anemia.
    ONS News; 2003 Apr 01; 18(4):5. PubMed ID: 12703245
    [No Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69. A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD.
    Toto R, Petersen J, Berns JS, Lewis EF, Tran Q, Weir MR.
    J Am Soc Nephrol; 2021 Feb 01; 32(2):469-478. PubMed ID: 33288629
    [Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71. Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy.
    Heatherington AC, Dittrich C, Sullivan JT, Rossi G, Schueller J.
    Clin Pharmacokinet; 2006 Feb 01; 45(2):199-211. PubMed ID: 16485917
    [Abstract] [Full Text] [Related]

  • 72. Re: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
    VanAudenrode M.
    J Natl Cancer Inst; 2003 May 21; 95(10):761-2; author reply 762-3. PubMed ID: 12759400
    [No Abstract] [Full Text] [Related]

  • 73. Efficacy of Darbepoetin Alfa in the Treatment of Chemotherapy-Induced Anemia in Non-Hodgkin's Lymphoma.
    Gregory SA.
    Support Cancer Ther; 2006 Jul 01; 3(4):232-9. PubMed ID: 18632499
    [Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75. Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin.
    Keller F, Ludwig U, Czock D.
    Expert Opin Drug Metab Toxicol; 2015 Jan 01; 11(1):139-47. PubMed ID: 25466552
    [Abstract] [Full Text] [Related]

  • 76. What caused excess strokes in patients randomized to darbepoetin in the trial to reduce cardiovascular events with Aranesp therapy (TREAT)?: no smoking gun.
    Winkelmayer WC.
    Circulation; 2011 Dec 20; 124(25):2805-8. PubMed ID: 22184042
    [No Abstract] [Full Text] [Related]

  • 77. Monitoring distributional assumptions and early stopping for a prospective clinical trial using Monte Carlo simulation.
    Gebski V, McNeil D, Coates A, Forbes J.
    Stat Med; 1987 Sep 20; 6(6):667-78. PubMed ID: 3685721
    [Abstract] [Full Text] [Related]

  • 78. [Review of results obtained from tumors unresponsive to chemotherapy].
    T'Jean M.
    Rev Med Liege; 1984 Feb 01; 39(3):103-7. PubMed ID: 6718861
    [No Abstract] [Full Text] [Related]

  • 79. Appropriate chemotherapy for palliating advanced cancer.
    Rubens RD, Towlson KE, Ramirez AJ, Coltart S, Slevin ML, Terrell C, Timothy AR.
    BMJ; 1992 Jan 04; 304(6818):35-40. PubMed ID: 1370911
    [No Abstract] [Full Text] [Related]

  • 80. Concentration- or effect-controlled clinical trials with sparse data.
    Levy G, Ebling WF, Forrest A.
    Clin Pharmacol Ther; 1994 Jul 04; 56(1):1-8. PubMed ID: 8033486
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.